Glen Scott
Neurology · West Columbia, SCNPI 1184656233
Payments from drug & device makers
Across 691 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$892
- AbbVie$747
- Eisai Inc.$693
- Novartis$612
- AstraZeneca$552
- Biogen$511
- plus $8K from 54 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$651%
- Food & beverage$11,71597%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,050 in reported general payments places this provider in the 75th percentile of 270 neurology providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 25 | $274,048 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 26 | $230,130 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $178,129 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 29 | $176,129 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $157,392 |
| Actemra ActpenTocilizumab | 20 | $80,858 |
| ActemraTocilizumab | 22 | $57,336 |
| NuplazidPimavanserin Tartrate | 12 | $48,990 |
| QuliptaAtogepant | 38 | $43,032 |
| XcopriCenobamate | 16 | $33,004 |
| FycompaPerampanel | 27 | $31,728 |
| BotoxOnabotulinumtoxina | 33 | $31,239 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $30,490 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $23,056 |
| Topiramate ErTopiramate | 13 | $19,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra, Privigen | $437 | $335,52128 claims |
| PfizerPanzyga, Nurtec Odt, Eliquis | $222 | $264,09861 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $171 | $176,12929 claims |
| AbbVieQulipta, Botox | $747 | $74,27171 claims |
| Genentech, Inc.Actemra | $40 | $57,33622 claims |
| Acadia Pharmaceuticals IncNuplazid | $440 | $48,99012 claims |
| SK Life Science, Inc.Xcopri | $238 | $33,00416 claims |
| Eisai Inc.Fycompa | $693 | $31,72827 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $65 | $23,05615 claims |
| UCB, Inc.Briviact | $472 | $17,34012 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $158 | $14,51911 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $34 | $2,29539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 270 neurology providers in South Carolina.
Other neurology in West Columbia
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
- Nicholas MilanoCharleston$1.1M
- Howard MandellRock Hill$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.